WSJ : North Korea Built an Alternative Financial System Using a Shadowy Network

North Korea Built an Alternative Financial System Using a Shadowy Network of Traders
Regime moves millions of dollars around the world despite sanctions and pressure on international banks

It was a familiar problem for North Korea.

A timber company it controlled in Africa had earned $100,000 by selling wood to a Chinese firm. Pyongyang needed the money to pay its foreign suppliers of oil and other critical products.

But U.S. and international sanctions, intended to force North Korea to give up its nuclear program, limit its access to the global financial system. So it turned, U.S. authorities say, to an illicit workaround.

Instead of collecting the $100,000 itself, North Korea asked the Chinese customer to wire it to a commodities trader in Singapore, who could then use it to buy goods on Pyongyang’s behalf, according to a complaint filed last month by U.S. prosecutors seeking to confiscate related funds. The rest of the world would have no clue North Korea was even in the picture.

The alleged scheme, which American prosecutors say has been used repeatedly in recent years, shows how North Korea has built a shadowy alternative financial system that allows it to continue doing business on the global stage.

U.S. officials, United Nations investigators and experts tracking the money flows say Pyongyang has succeeded in buying and selling products including oil, coal and tobacco despite rules designed to exclude it from dollar-based trade.

The machinations are central to the Kim Jong Un regime’s efforts to evade U.S. and U.N. sanctions and keep the country’s economy afloat. The Wall Street Journal has previously detailed how North Korea orchestrates complex shipping maneuvers to transport goods undetected, relies on webs of front companies to disguise its activities and earns millions of dollars selling military training and computer-programming services.

One of North Korea’s biggest challenges has been to move dollars around the world despite sanctions and pressure on international banks to crack down on money laundering. Its solution has been to keep earnings in the hands of overseas associates whose ties to North Korea are hidden. Those associates then make the transactions that flow through banks in the U.S., which typically must clear wire transfers involving U.S. dollars.

“Only a small amount of money enters North Korea,” says Joshua Stanton, a Washington lawyer who helped draft recent U.S. sanctions laws against the country. “Most of it sits in foreign banks and moves around.”

North Korean officials at the country’s permanent mission to the United Nations Office in Geneva didn’t respond to requests for comment.

A review of recent indictments and complaints by the Justice Department and actions by the Treasury Department and the U.N. panel of North Korea experts suggest the arrangements are integral to the North Korean regime’s survival—and that they keep evolving as Washington ramps up pressure.

According to the forfeiture case filed last month by federal prosecutors in Washington, which seeks to confiscate funds held in a U.S. bank, payments from a Hong Kong-registered buyer of North Korean paraffin wax allegedly went to a Russian company supplying Pyongyang with oil. A similar case brought by U.S. authorities alleges that North Korea used a Chinese coal importer that owed it money to pay for communications gear from China’s ZTE Corp. A Washington federal judge in September granted the government’s request to confiscate funds linked to that case. A ZTE spokesman declined to comment for this article. In other cases, prosecutors say companies in the British Virgin Islands and elsewhere supplied North Korea with sugar and urea fertilizer.

Washington has levied sanctions against some companies and individuals accused of moving money for Pyongyang, and it is considering further actions focusing on Chinese banks, people familiar with the matter said. It has directed U.S. banks, which Treasury said in a report this month “face complications” in identifying the underlying North Korea links, to watch for illicit tactics.

In a 2016 complaint, U.S. prosecutors said Standard Chartered PLC, Deutsche Bank AG and other banks in the U.S. processed transfers that involved a sanctioned North Korean bank. The complaint, seeking the forfeiture of funds from bank accounts in China, didn’t allege wrongdoing by the Western banks.

In a written statement, China’s Foreign Ministry reiterated its longstanding position that the government implements U.N. resolutions related to North Korea. Spokeswomen for Standard Chartered and Deutsche Bank declined to comment.

A 2017 order by a federal judge in Washington said that in the past decade, eight banks in the U.S. processed $700 million linked to just one China-based network acting on Pyongyang’s behalf, with more than $50 million flowing in seven months during 2016 and 2017.

U.S. bank executives say that despite their anti-money-laundering processes, it can be hard to stop North Korea-related transfers because, as clearing banks, they are one step removed from the companies that help Pyongyang. Those transfers originate in banks outside the U.S., in many cases in China.

In the 2000s, Washington barred U.S. institutions from dealing with Banco Delta Asia, a Macau bank that handled North Korean funds, and went after North Korean banks that supported the country’s nuclear program. The U.S. and U.N. later added rules to make dollar-based trade even harder for North Korea. The restrictions hurt Pyongyang because sellers of commodities it needs, including oil, normally demand to be paid in U.S. dollars.

North Korea is increasingly breaking its transfers into smaller quantities to make it more difficult to stop them all, according to U.S. officials tracking North Korean money. It also is getting more skilled at providing fake documents to banks, the officials said. When a company helping it gets sanctioned, Pyongyang finds or creates new ones, they said.

The chain of transactions described in the forfeiture case originated last year in Equatorial Guinea, where Pyongyang controlled a company that used North Korean workers to make plywood and veneer. A 2006 report in North Korean state media described a seminar held on the company’s premises about the writings of then-leader Kim Jong Il. The company’s name, Chilbo, is the name of a North Korean mountain.

Equatorial Guinea said in a report to the U.N. that it shut down Chilbo’s activities this year to comply with U.N. sanctions. Before that, Chilbo had a Chinese customer called Yuanye Wood Ltd., U.S. prosecutors said last month in the forfeiture complaint.

Wiring dollars to Chilbo likely would have set off alarms at U.S. banks, given the timber company’s North Korea links. So Chilbo instructed Yuanye to send payment to an intermediary then untouched by U.S. sanctions, according to the complaint, which seeks to seize $1.7 million in Yuanye Wood’s funds frozen at an unnamed bank in the U.S.

“The complaint alleges Yuanye Wood is being directed by Chilbo,” the U.S. prosecutor, Zia Faruqui, said in an interview. “They say, ‘OK, Chilbo, who do I pay today?’ ”

According to the complaint, the money went to a Singaporean family-run business called Wee Tiong (S) Pte Ltd., a fixture in the local commodities trade. The co-owner, Tan Wee Beng, 41 years old, received an Ernst & Young entrepreneurship award in 2011, and local media has since chronicled his efforts to modernize the business.

Over that same period, Mr. Tan was helping North Korea launder millions of dollars, according to separate criminal charges filed against him by federal prosecutors in Manhattan, which were unsealed in October. Treasury Secretary Steven Mnuchin said at the time that Mr. Tan “made deliberate efforts to launder money through the U.S. financial system on behalf of North Korea.”

The Manhattan prosecutors and the Federal Bureau of Investigation allege he worked with sanctioned North Korean entities and took steps to obscure the source of the funds. He then would supply goods to Pyongyang, at times using his own tankers for delivery, U.S. officials say.

Efforts to reach Mr. Tan in person at his Singapore office and home were unsuccessful. An employee at the office said the owners hadn’t been coming in and were working remotely. Mr. Tan referred emailed questions to his lawyers in Singapore, who responded that “it would not be appropriate at this stage for him to engage publicly with the press.”

His company, Wee Tiong, sued the FBI in July 2017, denying it had acted on behalf of North Korea. It alleged the FBI’s communications with multiple banks about the firm had harmed its business, which relied on institutions in the U.S., including Wells Fargo & Co., JPMorgan Chase & Co. and Deutsche Bank, to process dollar payments.

JPMorgan declined to process several U.S. dollar wire transactions involving Wee Tiong to avoid the risk of processing transfers that could involve North Korea, a person familiar with the transactions said. Deutsche Bank and Wells Fargo declined to comment.

Wee Tiong withdrew the lawsuit after the FBI clarified to the banks that the company hadn’t been blacklisted by the Treasury Department. Fourteen months later, Treasury sanctioned Wee Tiong, cutting it off from the U.S. financial system.

The Singapore police said in an emailed response to the Journal that they are investigating the matter and would take “appropriate action.”

Efforts to locate representatives of Yuanye Wood, the alleged buyer of the wood, at an address in Wenzhou, China, listed on the U.S. complaint were unsuccessful.

Around the time Mr. Tan was facing difficulties with money transfers, North Korean banks made preparations to pay a different supplier, this one in Russia, according to the forfeiture complaint filed last month that alleges dozens of illicit transactions involving Pyongyang. In May of last year, prosecutors allege, North Korean banks directed a Hong Kong-registered company that bought paraffin wax, used for making candles and other products, from North Korea to pay a front company instead of paying Pyongyang.

Ten days later, that company transferred $1.2 million to a third company, Velmur Management Pte. Ltd., according to the complaint. The transaction was labeled “prepayment for gasoil,” the complaint said.

In Singapore’s corporate registry, Velmur is listed as a real-estate company also involved in oil transport. There was no answer at the door during a recent visit to the 66th-floor apartment listed as its Singaporean address. Its sole listed shareholder is a Russian, Ruslan Larin, with an address in the Moscow region. A woman who recently answered the door there said Mr. Larin hasn’t appeared in a long time.

In a previous forfeiture complaint, U.S. authorities alleged Velmur was a conduit set up so that sanctioned North Korean banks could pay a Russian oil company to transport diesel fuel to North Korea. To banks, it would look like a Singaporean company was dealing with a Russian one, with no North Korean footprint.

The buyer of the North Korean paraffin created false invoices for its Chinese bank claiming it had purchased wax from the companies to which it was sending money, even though those companies weren’t in the wax trade, prosecutors said.

“When you find a good blackjack table that is paying out, everyone goes and tries to cash that out,” said Mr. Faruqui, the federal prosecutor, referring to North Korean banks’ search for collaborators. “When you find a front company that you can push U.S. dollars through, and you’re a North Korean bank, you’re going to use it for everything.”

WSJ : Chinese Gene-Editing Experiment Loses Track of Patients, Alarming Technolo

Chinese Gene-Editing Experiment Loses Track of Patients, Alarming Technology’s Inventors
Use of Crispr-Cas9 tool in trials also draws attention of health authorities in Beijing amid international concern

Chinese scientists have raced ahead in experimenting with gene-editing on humans in the last few years, using a powerful new tool called Crispr-Cas9 to edit the DNA of dozens of cancer patients.

Information gathered by The Wall Street Journal shows one such trial has lost touch with patients whose DNA was altered, alarming some Western scientists who say subjects should be monitored for many years.

In another trial, an Indian man’s cancer improved but he suffered a heart attack and brain stroke; Chinese doctors didn’t investigate the cause, the deceased man’s family said.

Now, these and other Crispr trials are coming under scrutiny for the first time from health authorities in Beijing after a controversial gene-editing announcement in China last month sparked international concern over whether there is adequate regulation and oversight in the country.

Three doctors involved with Crispr trials in China told the Journal they received inquiries from the nation’s science and health ministries in recent weeks asking for details about their trials. Neither ministries responded to requests for comment.

Unlike in the U.S., no federal body is overseeing these trials in China, meaning standards vary across experiments.

The approach is troubling for many doctors in the U.S. who fear missteps with early trials could set back development of the promising science by years.



Crispr holds the promise to correct intractable diseases by rewriting a person’s genetic code, or DNA. But it isn’t foolproof and can cause changes in genes other than the ones sought. Unintended consequences could surface years later, American scientists have warned, emphasizing the need to follow up with patients long term.

Jennifer Doudna, a biochemistry professor at the University of California, Berkeley and one of the inventors of the gene-editing tool, said long-term monitoring of subjects is vital and failure to medically investigate deaths is unacceptable.

“Since we do not fully understand the human genome and are still developing knowledge of Crispr-Cas technology, we need to monitor the intended and unintended consequences over the lifespan of patients,” she said.

Feng Zhang, another inventor of the tool and a molecular biologist at the Broad Institute of MIT and Harvard, described the Journal’s findings surprising, noting that tests on patients hinge on rigorous trial design and follow-ups.

Beijing’s increased scrutiny comes after a Shenzhen-based scientist last month announced that he had used the same tool to engineer the world’s first gene-edited babies. Using Crispr to modify the genes of embryos is more controversial than modifying the genes of terminally ill patients because any changes in embryos are likely to pass onto future generations, meaning a tiny blip could have far-reaching consequences.

Beijing officials have said implanting such an embryo into a human is illegal and that it is separately investigating the scientist, who claimed to have birthed twin girls resistant to HIV last month.

Using Crispr to modify adults’ DNA isn’t illegal in China or the U.S., but American scientists have proceeded with greater caution. The U.S. cleared its first Crispr trial only this year even though the technology was partly invented there in 2012. China’s earliest known Crispr trial began in 2015.

It took the University of Pennsylvania, one of the first in the world to publicly announce a Crispr trial, two years to receive clearance from bodies ranging from its institutional review board to the Food and Drug Administration. Reviewers ordered additional lab tests and examined the wording on consent letters, among other things, before agreeing to let the school enroll patients this year.

Even then, the university struggled to recruit patients for months afterward because the requirements were so stringent. It plans to follow patients for 15 years, as recommended by the FDA for gene therapy trials. The FDA recently cleared two more Crispr trials.

In China, doctors can proceed after a go-ahead from their hospital’s ethics committees. By January 2018, a dozen such trials were publicly listed, the Journal reported at the time, and at least 86 late-stage cancer patients’ genes were edited. Most were treated thanks to Anhui Kedgene Biotechnology Co., a private startup that provided the Crispr technology and lobbied hospitals to open trials testing it.

More patients have had their genes edited since, according to doctors involved in those tests, though none of China’s Crispr trials have published results.

One of Kedgene’s projects has lost touch with patients whose DNA was altered, according to a person familiar with the matter. Kedgene founder Mandy Zhou said one trial didn’t complete the research as planned, and as a result lost touch with patients. No patients died during treatment in that trial, she added.

Another Kedgene trial, at the Anhui Provincial Hospital, treated 18 patients, according to Wang Yong, who ran it. Many participants died as their cancer grew, Dr. Wang said, without giving a specific number. Dr. Wang said he was asked by the science ministry this month to send a report on the trial, the first time authorities in Beijing sought information about it since it began more than a year ago.

Kedgene’s Dr. Zhou said some patients had far outlived their expected survival span and none of the deaths were related to the gene editing. She didn’t respond to questions about the basis for reaching that conclusion.

At least 19 out of the 21 patients involved in a third Kedgene trial that opened this year have died, according to Wu Shixiu of the Hangzhou Cancer Hospital, who led it. Dr. Wu said the deaths were unrelated to the use of Crispr, without giving further details.

One man who died was Sanjit Kumar Samal, an Indian government official who, after exhausting other treatments in his home country, flew to China in a bid to contain his fast-spreading esophageal cancer.

Mr. Samal began improving after receiving the first Crispr-modified blood infusions, according to his brother who accompanied him for treatment. The 57-year-old’s disease-fighting white blood cells were drawn, reprogrammed with Crispr to delete a gene that interferes with the immune system’s ability to fight cancer, then re-injected into his body.

After the second infusion, “Dr. Wu came running to tell us the results,” said the brother, Ajit Samal. The results showed that “90% of his tumor had gone; hardly anything was left,” he said, noting that his brother reported feeling better. “It was like a miracle,” he said. “No one could believe it.”

Six weeks later in September, Mr. Samal died in India. Indian doctors declared he had suffered a heart attack and brain stroke, according to his brother. Mr. Samal, who didn’t have a known prior heart condition, was due to return to China for a third infusion.

Dr. Wu said he was aware that Mr. Samal had died of a heart condition. He didn’t ask the family for any medical results following his death in India, according to Mr. Samal’s brother.

Dr. Wu didn’t respond to requests for further comment after news of the gene-edited babies surfaced, including on whether he had requested medical data on Mr. Samal’s death. In earlier interviews, Dr. Wu said he attempted to publish his research, but that some Western academic journals declined to accept it. He didn’t elaborate.

“Any death in any clinical trial must be fully investigated,” said Berkeley’s Dr. Doudna. She said she is concerned “about reckless applications of genome editing that put the safety of patients at risk, damages the public’s acceptance of Crispr technology, and could trigger a range of negative but permanent unintended consequences.”

The Samal family doesn’t pin blame on the experimental therapy. Instead, the deceased Mr. Samal’s brother said he would advise other cancer sufferers to seek the same treatment.

>>> US Close Dow -0.33% S&P -0.12% Nasdaq +0.08% Russell +0.46% VIX -5.41% @ 28.


Closing Market Summary: Stocks Trade Mixed to Close Volatile Week

The S&P 500 lost 0.1% on Friday in what was another whipsaw day of trading that saw the S&P 500 up as much 1.3% at its high and down as much as 0.6% at its low. The benchmark index finished a remarkably volatile, and history-setting, week with a gain of 2.9%.

The Dow Jones Industrial Average (-0.3%), the Nasdaq Composite (+0.1%), and the Russell 2000 (+0.5%) also experienced roller-coaster action on Friday and finished with weekly gains of 4.0%, 3.8%, and 3.6%, respectively.

Price action was relatively tame (for this week anyway) after the S&P 500 fumbled an early rally effort shortly after the start of trading. However, at around 1:30 p.m. ET, the benchmark index climbed from a loss of 0.2% to as high as 1.3% without any news to account for the move.

All sectors were up and all major indices were higher.

Nevertheless, stocks would retreat just as quickly as they had climbed with no news catalysts to account for the subsequent downturn either.  It was perhaps fitting that the S&P 500 ended the session close to where it started as that was an accurate reflection of the lack of conviction that characterized today's trading action.

Efforts to flatten out positions in front of the weekend, which could be a four-day weekend for many (the market is open December 31 and closed January 1) were likely responsible for some of the late-day selling.

The S&P 500 sectors finished mixed with energy (-0.9%) and materials (-0.6%) underperforming the broader market. Conversely, the consumer discretionary (+0.3%) and real estate (+0.2%) sectors outperformed.

U.S. Treasuries remained resilient to selling pressure with the 2-yr yield and 10-yr yield decreasing one basis point each to 2.52% and 2.74%, respectively. The U.S. Dollar Index lost 0.1% to 96.34.

Reviewing Friday's economic data, which included Pending Home Sales for November and the Chicago PMI for December:

  • Pending Home Sales decreased 0.7% in November (consensus +0.5%). Today's reading follows an unrevised 2.6% decrease in October.
  • The MNI Chicago Business Barometer, colloquially known as the Chicago PMI, decreased to 65.4 in December from 66.4 in November. The December pullback took place after the Index soared by nearly eight points in November.
    • The key takeaway from the report is that the overall reading remained elevated thanks to strong order backlogs and an increase in the Production Index.

Investors will not receive any notable economic data on Monday, which will be a full day of trading on Wall Street.

  • Nasdaq Composite -4.6% YTD
  • Dow Jones Industrial Average -6.7% YTD
  • S&P 500 -7.0% YTD
  • Russell 2000 -12.9% YTD

>>> US Early premarket gappers


Early premarket gappers

Gapping up:
  • OPK +14.6%, APHA +11.3%, BTI +3.8%, FRC +3.5%, WING +1.9%, adbe +1.9%, MJ +1.3%, SPY +0.8%, QQQ +0.7%, DIA +0.7%, MO +0.6%, TLRY +0.5%, PM +0.5%

Gapping down:

  • UNIT -1.6%

FT : US needs multilateralism as much as its partners

US needs multilateralism as much as its partners
As new risks loom, global co-operation needs to be revived in 2019

At the G20 summit in Argentina in November, it was counted as a major achievement that the assembled world leaders were able to produce a joint communiqué. That normally routine task had proved beyond the leaders who had assembled a few weeks earlier at the Asia-Pacific Economic Cooperation meeting in Papua New Guinea. There was also no final communiqué agreed at the G7 summit in Canada earlier in the year.

The fact that world leaders are finding it so hard to agree on common forms of words, however bland, is troubling. It points to a breakdown in trust and the mechanisms of international co-operation. That state of affairs must improve over the coming year — or the world will be dangerously vulnerable to an economic or financial crisis that might require a co-ordinated global response. Even without an emergency, the leaders of the world’s largest economies will need to rediscover the habit of co-operation or the world could drift into an intensified trade war.

A key sign of the health (or otherwise) of international governance will be how well the G20 functions in 2019, when Japan will chair it. The Japanese can potentially play the role of bridge-builders, as close allies of US and also major trading partners of China. For while it is clear the most important discussions on the US-China trade dispute will take place directly between Washington and Beijing, the whole world has a stake in the outcome.

Major trading powers, such as Japan and the EU, should continue to insist on the importance of maintaining a rules-based trading system, with the WTO at its core. They can put pressure on China on questions such as intellectual property theft, while pushing back against the unilateral imposition of US tariffs, sometimes on dubious national security grounds. The G20, as well as the G7, can be important forums for re-stating shared principles and putting collective pressure on both the US and China to respect international norms.

Cynics might dismiss international summits as pointless gatherings that specialise in producing meaningless verbiage. Such scepticism misses the point. At moments of crisis, it is crucial that world leaders are able to work together. That was never more evident than in the first two G20 summit meetings, held in Washington and London in 2008 and 2009. By co-ordinating their response to the global financial crisis, international leaders were able to send a reassuring signal to the markets and to pump growth back into the global economy. In doing so, they probably prevented a severe economic shock from turning into a global depression.

But those were different times, when the leaders of the US and China were not locked into a trade war; and when populists were not in power in important G20 countries, such as Italy, Mexico and Brazil. It is an open question whether world leaders will be able to respond as effectively to a new crisis.

For all the Trump administration’s insistence on bilateralism, not multilateralism, as its preferred method of international diplomacy, even the US ultimately needs a functioning multilateral order. Some international issues simply cannot be fixed bilaterally.

These include environmental issues such as climate change, though these appear to weigh little in the Trump White House. They also encompass critical economic issues, such as trade and the functioning of the international financial system. US power can be brought to bear to fix specific grievances with trading partners. But multilateral co-operation is needed to maintain an open global economy. That principle needs to be remembered and upheld in the coming year.